Wendy Van De Ven MSc, Abstract Co-Author: Nothing to Disclose

Michiel Sedelaar MD, PhD, Abstract Co-Author: Nothing to Disclose

Jurgen J. Futterer MD, PhD, Abstract Co-Author: Nothing to Disclose

Henkjan Huisman PhD, Presenter: Stockholder, QView Medical, Inc

Focally targetted magnetic resonance imaging (MRI) guided trans rectal ultrasound (TRUS) biopsy of the prostate with a commercially available ultrasound machine that has electromagnetic tracking (EM) fusion: is less accurate than MR guided biopsy, but non-inferior for targets larger than 9 mm, can optimize accuracy using focal landmarks near the target location, can be performed within 10 minutes.

Prostate anatomy deformation differs between MRI and TRUS. EM tracking, rigid fusion cannot compensate for this, resulting in a low overall fusion accuracy. Focal structures are visible in both MR and TRUS, when used landmarks, they can enhance accuracy near the target. Prostate cancer lesions are often heterogenous. The most aggressive part of the lesion should be targetted. MRI can localize these aggressive areas. T2w MRI is sent to the US machine that can synchronously visualize it with the live ultrasound. Using fusion landmarks near the target the biopsy accuracy can be optimized. We are currently evaluating this MR-TRUS biopsy method in comparison to MR guided biopsy. We include targets larger than 9 mm. The procedure has been succesfully performed in 5 patients. This cost-effective biopsy method seems non-inferior to MR guided biopsy for targets of sufficient size.

http://abstract.rsna.org/uploads/2014/14007093/14007093_kc2k.pdf

Van De Ven, W, Sedelaar, M, Futterer, J, Huisman, H, Focally Targeted Magnetic Resonance Imaging Guided Transrectal Ultrasound Biopsy of the Prostate with an Ultrasound Machine That Has Electromagnetic Tracking Fusion.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14007093.html